ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
Semagacestat (LY450139) is a novel γ-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.
Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.
Corey R
CR
Hopkins
D000409:Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000502:physiology; D016229:Amyloid beta-Peptides / Q000097:blood / Q000134:cerebrospinal fluid; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D001381:Azepines / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015394:Molecular Structure; D015337:Multicenter Studies as Topic; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D010446:Peptide Fragments / Q000097:blood / Q000134:cerebrospinal fluid; D011499:Protein Processing, Post-Translational; D051880:Receptors, Notch / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D001381:Azepines; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D051880:Receptors, Notch; C078592:amyloid beta-protein (1-40); D053829:Amyloid Precursor Protein Secretases; D000409:Alanine